EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD ?

Christoph Schubart iD, Lars Tögel, Maria Giulia Carta, Philip Hetzner, Lina Helbig, Charlotte Zaglas, Maria Ziegler, Robert Stöhr, Annett Hölsken, Juliane Hoyer, Fulvia Ferrazzi, Clemens Neufert und 15 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Christoph Schubart und 26 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Hauptthemen laut MEDLINE: Neoplasms, Recombinational DNA Repair. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Illumina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alterations in Homologous Recombination Repair (HRR) Pathway genes have been found to be associated with HR‐Deficiency (HRD), which is an approved biomarker for PARP Inhibitor (PARPi) treatment. The aim of a Molecular Tumor Board (MTB) is to identify molecular alterations in cancer patients with advanced tumors that may suggest off‐label treatment options. So far, few studies have analyzed the presence of HRR gene mutations and their association with HRD outside of clinical studies. Currently, no data on HRD testing in the setting of a MTB have been published. For the present study, a cohort of 237 patients encompassing 24 different tumor entities was collected from the MTB of the Comprehensive Cancer Center Erlangen‐EMN. We show that an elevated Genomic Instability Score (GIS ≥42) can occur in samples with and without mutations in HRR‐related genes. Overall, 38.1% of cancer samples with BRCA1/2 mutations, 10.9% of tumors with alterations in HRR genes other than BRCA1/2 , and 4.3% of cancer samples without HRR gene mutations harbored an elevated GIS. Notably, our data show that various inactivating BRCA1/2 mutations are not associated with an elevated GIS. Taken together, panCancer assessment of HRD in addition to BRCA1/2 and other HRR gene mutational analysis is recommended to guide decisions regarding PARPi treatment. Further studies are needed to establish thresholds for GIS in non‐ovarian cancer entities. Finally, HRD can be observed in 4.3% of BRCA1/2 and other HRR gene wildtype cancer samples, and may emerge as an independent biomarker for PARPi in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsRecombinational DNA RepairHumansMutationFemaleGenomic InstabilityBiomarkers, TumorBRCA2 ProteinMalePoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinMiddle AgedAgedAdult

Stichwörter der Autor:innen

HRDTSO 500‐HRDmolecular TumorboardpanCancer

Substanzen

Biomarkers, TumorBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsBRCA2 protein, humanBRCA1 ProteinBRCA1 protein, human

Autor:innen und Institutionen

  • Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
  • CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany.
  • Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
  • Zentrum Personalisierte Medizin Erlangen (ZPM-Erlangen), Erlangen, Germany.
  • Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

ORCID-Profile: Christoph Schubart, Marianne Pavel, Evgeny A Moskalev

Förderung

  • Illumina

Zitieren

APA

Schubart, C., Tögel, L., Carta, M. G., Hetzner, P., Helbig, L., Zaglas, C., Ziegler, M., Stöhr, R., Hölsken, A., Hoyer, J., Ferrazzi, F., Neufert, C., Lettmaier, S., Pavel, M., Golcher, H., Mueller, S. K., Fuchs, F., Schulmeyer, C. E., Beckmann, M. W., …, & Moskalev, E. A. (2025). Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD ?. International Journal of Cancer. https://doi.org/10.1002/ijc.35457

Vancouver

Schubart C, Tögel L, Carta MG, Hetzner P, Helbig L, Zaglas C, et al. Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD ?. International Journal of Cancer. 2025. doi:10.1002/ijc.35457

BibTeX
@article{Schubart2025,
  author = {Schubart, Christoph and Tögel, Lars and Carta, Maria Giulia and Hetzner, Philip and Helbig, Lina and Zaglas, Charlotte and Ziegler, Maria and Stöhr, Robert and Hölsken, Annett and Hoyer, Juliane and Ferrazzi, Fulvia and Neufert, Clemens and Lettmaier, Sebastian and Pavel, Marianne and Golcher, Henriette and Mueller, Sarina K and Fuchs, Florian and Schulmeyer, Carla E and Beckmann, Matthias W and Wullich, Bernd and Agaimy, Abbas and Reis, Andre and Hartmann, Arndt and Meidenbauer, Norbert and Spoerl, Silvia and Haller, Florian and Moskalev, Evgeny A},
  title = {Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD ?},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35457}
}
Kostenlos starten →